医院住院PCI量与TAVR及TMVr临床结局的关联
基于2016年全国再入院数据库的横断面研究,纳入至少完成5例TAVR或5例TMVr的医院,按住院PCI量四分位分组,评估其与风险标化院内死亡率及30天再入院率的关联。结果显示,医院住院PCI量与TAVR或TMVr的上述结局均无显著关联。
要点
- 住院PCI量高低与TAVR风险标化院内死亡率及30天再入院率无关。
- 住院PCI量高低与TMVr风险标化院内死亡率及30天再入院率无关。
- 将PCI量最低标准纳入TAVR/TMVr国家覆盖决策尚需进一步证据支持。
核心结论
- 本研究中,医院住院PCI量与TAVR或TMVr的临床结局无关联。
研究设计与样本
- 基于2016年全国再入院数据库的 population-based 横断面研究。
- 按年住院PCI量四分位将医院分组,比较风险标化院内死亡率和30天再入院率。
主要发现
- 至少完成5例TAVR的283家医院中位住院PCI量为386例(IQR 299-571)。
- 至少完成5例TMVr的125家医院中位住院PCI量为451例(IQR 326-651)。
临床怎么用
- 对于开展TAVR或TMVr的医院,住院PCI量不宜单独作为预测手术结局的筛选指标。
- 国家覆盖决策中纳入PCI量最低标准前,需更多证据支持。
局限性
- 研究为横断面设计,仅使用2016年全国再入院数据库数据。
- 仅纳入至少完成5例TAVR或5例TMVr的医院,可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The US Centers for Medicare and Medicaid Services recently released an updated national coverage determination proposal for transcatheter aortic valve replacement (TAVR) that maintains a focus on hospital TAVR volume and percutaneous coronary intervention (PCI) volume, and the national coverage determination for transcatheter mitral valve repair (TMVr) also has PCI volume requirements. However, the associations between hospital PCI volume and TAVR and TMVr outcomes are unknown. OBJECTIVE: To investigate whether hospital inpatient PCI volume is associated with rates of risk-adjusted in-hospital mortality and 30-day hospital readmission after TAVR and TMVr. DESIGN, SETTING, AND PARTICIPANTS: This population-based cross-sectional study of the 2016 Nationwide Readmissions Database included procedures completed in hospitals with a minimum of 5 TAVR or 5 TMVr procedures between January 1, 2016, and November 30, 2016. EXPOSURES: Hospitals were divided into quartiles based on annual inpatient PCI volumes. MAIN OUTCOMES AND MEASURES: Primary outcomes were in-hospital mortality and 30-day readmission rates. The associations between hospital inpatient PCI quartile and outcomes were evaluated using Kruskal-Wallis tests. Risk adjustment for in-hospital mortality rates was done through inclusion of variables based on the Elixhauser comorbidity classification, and risk adjustment for 30-day readmission rates was done in accordance with the Hospital-Wide Readmission Measure methodology used by the Centers for Medicare and Medicaid Services for public reporting. RESULTS: There were 283 hospitals that performed at least 5 TAVRs, with a median inpatient PCI volume of 386 (interquartile range, 299-571) procedures, and 125 hospitals that performed at least 5 TMVr procedures, with a median inpatient PCI volume of 451 (interquartile range, 326-651) procedures. There was no association between hospital inpatient PCI volume and median TAVR risk-standardized in-hospital mortality (median [IQR] rates: bottom quartile, 1.82% [1.77%-1.90%]; second quartile, 1.81% [1.76%-1.86%]; third quartile, 1.81% [1.75%-1.90%]; top quartile, 1.82% [1.76%-1.91%]; P = .75) or the 30-day readmission (median [IQR] rates: bottom quartile, 13.6% [13.2%-14.3%]; second quartile, 13.3% [12.7%-14.0%]; third quartile, 13.5% [12.7%-14.3%]; top quartile, 13.8% [12.8%-14.3%]; P = .10) rates. Similarly, there was no association between hospital inpatient PCI volume and median TMVr risk-standardized in-hospital mortality rates (median [IQR] rates: bottom quartile, 1.84% [1.47%-2.53%]; second quartile, 1.65% [1.21%-3.02%]; third quartile, 1.80% [1.52%-3.58%]; top quartile, 1.76% [1.33%-4.20%]; P = .71) or 30-day readmission rates (median [IQR] rates: bottom quartile, 13.4% [13.1%-13.6%]; second quartile, 13.1% [12.9%-13.5%]; third quartile, 13.1% [12.9%-13.5%]; top quartile, 13.3% [12.8%-13.6%]; P = .30). CONCLUSIONS AND RELEVANCE: In this study, there was no association between inpatient PCI volume and TAVR or TMVr outcomes. Further evidence is needed to support inclusion of PCI volume minimums in national coverage determination requirements for hospital TAVR and TMVr programs.
引用
- Butala NM, Bucholz EM, Kolte D, et al. Association of Hospital Inpatient Percutaneous Coronary Intervention Volume With Clinical Outcomes After Transcatheter Aortic Valve Replacement and Transcatheter Mitral Valve Repair. JAMA Cardiol. 2020. PMID: 32049303. doi:10.1001/jamacardio.2019.6093
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。